Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

Ahmedabad: Zydus Lifesciences Limited, a life-sciences company, with an international presence, has announced that its wholly ...

Formycon will develop, register, manufacture, and supply the product, while Zydus will be responsible for commercialization.

MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.

Formycon AG will be responsible for the development, registration, manufacture and supply of the product. Zydus Lifesciences ...